Clinical trials: Nonalcoholic Fatty Liver
Non-Alcoholic Fatty Liver Disease
Probiotics in NASH Patients - PROBILIVER TRIAL
Non-alcoholic Fatty Liver Disease (NAFLD) is characterized by excessive accumulation of lipids in hepatocytes, not associated with alcohol consumption and ranges from hepatic steatosis to steatohepatitis, a form that can progress…
- Trial name
- NASH (NCT03467282)
- Testing
- Probiotic
- Where
- Brazil
- Volunteers
- 46 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Non-Alcoholic Fatty Liver Disease
Calisthenics Versus High Intensity Interval Training in NAFL
According to sample size calculation and after achieving the inclusion criteria, sixty patients with non-alcoholic fatty liver (NAFL) of both genders will be enrolled in this study and their ages will be ranged from30s-40s; they…
- Trial name
- NCT06032650
- Testing
- Calisthenics exercise and High intensity interval training
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Cairo University
NAFLD
Echocardiographic Findings as Markers of Subclinical Cardiac Dysfunction in Patients With Non-Alcoholic Fatty Liver Disease
The investigators aim to evaluate patients with NAFLD for early echocardiographic signs of myocardial dysfunction and if there is any correlation between the degree of steatosis or fibrosis and the degree of myocardial…
- Trial name
- NCT06130202
- Testing
- Echocardiographic findings
- Volunteers
- 165 people
- Sponsor
- Assiut University
NASH - Nonalcoholic Steatohepatitis, NAFLD
Characterization of the Platelet Inflammatory Response in NAFL and NASH
The primary objective of the study is to identify which features of platelet activation promote the inflammatory response that underlies the progression from NAFL to NASH. Therefore, the investigators plan: 1.
- Trial name
- NCT05128253
- Testing
- High fat meal in a subset of patients with NAFL or NASH
- Where
- 2 sites in Italy
- Volunteers
- 44 people
- Sponsor
- Stefania Basili
COVID-19
Mapping Organ Health Following COVID-19 Disease Due to SARS-CoV-2 Infection
A prospective, longitudinal, observational cohort study looking at patients following COVID-19 disease using multi-parametric magnetic resonance imaging (MRI) to assess the degree and prevalence of organ injury.
- Trial name
- COVERSCAN (NCT04369807)
- Testing
- Outpatient MRI
- Where
- 2 sites in United Kingdom
- Volunteers
- 693 people
- Sponsor
- Perspectum
Non-alcoholic Steatohepatitis
First-in-Human Study of GM-60106 in Healthy Adults and Otherwise Healthy Adults With an Increased Body Mass Index and Markers of Non-Alcoholic Fatty Liver Disease
This is a Phase 1a/1b, randomised, double-blind, placebo-controlled single- and multiple-ascending dose study to evaluate the safety, tolerability, PK, and PD of GM-60106 in healthy adult male and female participants and…
- Trial name
- NCT05517564
- Testing
- GM-60106
- Where
- 2 sites in Australia
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- JD Bioscience Inc.
Non Alcoholic Fatty Liver Disease
Mastiha Treatment for Obese With NAFLD Diagnosis
NAFLD/NASH is one of the most common complications of obesity and diabetes mellitus in Western populations affecting approximately 50% of diabetics and 76% of obese patients.
- Trial name
- MAST4HEALTH (NCT03135873)
- Testing
- Mastiha
- Where
- Greece
- Volunteers
- 100 people
- Sponsor
- Harokopio University
Fatty Liver Disease, Fatty Infiltration
Fatty Liver Among Employees at Banha University
This was cross sectional study at Banha University Hospital among employees. Age of the subjects from 20-60 years old both males and females .All investigations done plus abdominal ultrasound for grading of fatty liver and dopler…
- Trial name
- fattyliver (NCT04367012)
- Testing
- Abdominal Ultrasound
- Where
- Egypt
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Benha University
NASH - Nonalcoholic Steatohepatitis
A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in non-cirrhotic subjects with biopsy-proven F2 - F3 NASH.
- Trial name
- Harmony (NCT04767529)
- Testing
- Efruxifermin
- Where
- 55 sites in United States, Puerto Rico
- Volunteers
- 128 people
- Sponsor
- Akero Therapeutics, Inc
Obesity, m-Health
Weight Loss Effects of M-health App in Obesity Multidisciplinary Outpatient Clinic
This is a randomized, open, controlled, single-center trial to identify the weight loss effects of adding mobile health application in obesity multidisciplinary outpatient clinic.
- Conditions
- Obesity, m-Health, NAFLD
- Trial name
- NCT05168072
- Testing
- m-Health app, conventional outpatient obesity management
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH)
This clinical study was designed to evaluate the safety, tolerability, pharmacokinetics and efficacy of various single and combination treatments in adult patients with non-alcoholic fatty liver disease (NAFLD) who manifest a…
- Trial name
- NEXSCOT (NCT04147195)
- Testing
- LYS006, Tropifexor
- Where
- 10 sites in United States, Argentina and 1 more
- Volunteers
- 41 people
- Sponsor
- Novartis Pharmaceuticals
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)
This study will test a Regeneron study drug called ALN-CIDEB to find out whether it may help treat a liver disease called MASH. In this study, researchers are looking at the effect of ALN-CIDEB on reducing liver fat, liver…
- Trial name
- NCT07631637
- Testing
- ALN-CIDEB
- Where
- 16 sites in United States, Puerto Rico
- Volunteers
- 150 people
- Sponsor
- Regeneron Pharmaceuticals
Fatty Liver, Liver Fibrosis
Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis
The purpose of this interventional study is to evaluate the efficacy and tolerability of docosahexaenoic acid (DHA), Vitamin E and Choline in children or adolescents with well-characterized and liver biopsy confirmed nonalcoholic…
- Conditions
- Fatty Liver, Liver Fibrosis, Obesity, Metabolic Syndrome
- Trial name
- NCT01934777
- Testing
- Docosahexaenoic Acid plus Vitamin E plus choline
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
Non-alcoholic Steatohepatitis
Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis
The purpose of this study is to evaluate the efficacy and safety of berberine treatment on Non-alcoholic Steatohepatitis.
- Trial name
- EASYBEinNASH (NCT03198572)
- Testing
- Lifestyle intervention, Berberine
- Where
- 6 sites in China
- Volunteers
- 89 people
- Sponsor
- Fudan University
NASH - Nonalcoholic Steatohepatitis
AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis
This is a Phase 1b multi-center, randomized, double-blind, dose-ranging, placebo-controlled, adaptive study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD) of TERN-201 in patients with non-cirrhotic NASH.
- Trial name
- NCT04897594
- Testing
- TERN-201
- Where
- 11 sites in United States
- Volunteers
- 52 people
- Sponsor
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Non-Alcoholic Fatty Liver Disease, Obesity
Lifestyle Interventions for the Treatment of Non-alcoholic Fatty Liver Disease in Overweight and Obese Adults
Lifestyle intervention is the most important management of non-alcoholic fatty liver diseases (NAFLD) patients. Weight reductions of 5-10% can improve non-alcoholic steatosis and fibrosis.
- Trial name
- NCT03972631
- Testing
- Lifestyle education, Intensive lifestyle intervention, Hypocaloric low-carbohydrate diet plan
- Volunteers
- 292 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Non Alcoholic Fatty Liver Disease
The Effect of Exercise Intervention on Insulin Resistance in Non-alcoholic Fatty Liver Disease (NAFLD)
This project examines the effects of a 4 month structured exercise intervention program in patients with non-alcoholic fatty liver disease (NAFLD).
- Trial name
- NCT01834300
- Testing
- Unsupervised exercise training, Supervised exercise training
- Where
- 7 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- University of Liverpool
Nonalcoholic Steatohepatitis
Betaine in Patients With Nonalcoholic Steatohepatitis
To assess the safety and efficacy of betaine in patients with NASH on markers of disease severity such as liver histology, liver biochemistries, and health related quality of life.
- Trial name
- NCT00586911
- Testing
- Cystadane
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Mayo Clinic
NAFLD
Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
BRB-018-001 is a multicenter, adaptive design, randomized, parallel group study to evaluate the safety, tolerability, and PK of repeat IV doses of RYI-018 in subjects with NAFLD.
- Trial name
- NCT03261739
- Testing
- RYI-018
- Where
- 6 sites in United States, Australia and 1 more
- Volunteers
- 84 people
- Sponsor
- Bird Rock Bio, Inc.
Insulin Resistance, NAFLD
Reversal of Lipid-Induced Insulin Resistance
The purpose of this study is to examine whether weight reduction decreases intramyocellular (IMCL) and hepatic lipid content, and improves insulin sensitivity of muscle and fat tissue in people who are insulin resistant and have…
- Trial name
- NCT02193295
- Testing
- Caloric Restriction
- Where
- 2 sites in United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Yale University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.